C

Cutia Therapeutics
HKEX:2487

Watchlist Manager
Cutia Therapeutics
HKEX:2487
Watchlist
Price: 6.83 HKD -2.01% Market Closed
Market Cap: 2.2B HKD
Have any thoughts about
Cutia Therapeutics?
Write Note

Cutia Therapeutics
Total Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Cutia Therapeutics
Total Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
C
Cutia Therapeutics
HKEX:2487
Total Liabilities
ÂĄ357.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Total Liabilities
ÂĄ16B
CAGR 3-Years
13%
CAGR 5-Years
36%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Total Liabilities
ÂĄ7.9B
CAGR 3-Years
20%
CAGR 5-Years
31%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Total Liabilities
ÂĄ3B
CAGR 3-Years
47%
CAGR 5-Years
45%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Total Liabilities
ÂĄ23.3B
CAGR 3-Years
27%
CAGR 5-Years
32%
CAGR 10-Years
64%
Imeik Technology Development Co Ltd
SZSE:300896
Total Liabilities
ÂĄ504.4m
CAGR 3-Years
72%
CAGR 5-Years
51%
CAGR 10-Years
N/A
No Stocks Found

Cutia Therapeutics
Glance View

Market Cap
2.1B HKD
Industry
Biotechnology

Cutia Therapeutics is a holding company that engages in the research and development of dermatology treatment solutions and products through its subsidiaries. The company is headquartered in Shanghai, Shanghai and currently employs 175 full-time employees. The company went IPO on 2023-06-12. The firm is committed to developing comprehensive solutions to meet the diverse needs of patients and consumers in a wide range of dermatological treatment and care markets. The firm is mainly engaged in clinical trials of its core product CU-20401. This product is mainly used to treat submental fat accumulation. The firm conducts its businesses in the domestic market and overseas markets.

Intrinsic Value
11.5 HKD
Undervaluation 41%
Intrinsic Value
Price
C

See Also

What is Cutia Therapeutics's Total Liabilities?
Total Liabilities
357.8m CNY

Based on the financial report for Dec 31, 2023, Cutia Therapeutics's Total Liabilities amounts to 357.8m CNY.

What is Cutia Therapeutics's Total Liabilities growth rate?
Total Liabilities CAGR 1Y
-87%

Over the last year, the Total Liabilities growth was -87%.

Back to Top